Biogen: more positive data in Alzheimer's

(CercleFinance.com) - Biogen has announced that its Aduhelm continued to reduce two key Alzheimer's disease pathologies, amyloid beta plaques and plasma p-tau181, in patients treated for up to two and a half years in the long-term extension phase of Phase III trials.


The data also show that in both phase III trials, at 78 weeks, patients with reduced plasma p-tau181 levels had less clinical decline than those with unreduced plasma p-tau181 levels.

This long-term phase III extension study was presented today at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD 2022) in Barcelona, 15-20 March.


Copyright (c) 2022 CercleFinance.com. All rights reserved.